Device China DeviceChina - Home 中文版 zhuce showcase Frequently Asked Questions camdi.org 主页 English Language 注册参会 路演报名 疑问解答

2018年赞助商

会议根据您公司的市场需求及预算提供多种合理的赞助方案,帮助您的公司向数百名医疗器械行业的管理者们展示实力。如果您有兴趣成为我们的赞助商或展商,请通过电子邮件sunh@biobay.com.cn与孙浩先生联系。

2018年赞助商

金牌赞助商

波士顿科学

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.

About Boston Scientific in China

Boston Scientific established its China headquarters in Shanghai in 1997 and now has branches and R&D centers in Beijing, Shanghai and Guangzhou. Core Boston Scientific businesses in China include cardiac intervention, structural heart, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral interventions and oncology, urology and women’s health, and asthma. As an R&D leader, the company provides high performance medical products and solutions for the prevention, diagnosis and treatment of assorted diseases and conditions. Boston Scientific strives to provide the most innovative global medical technology that is custom-tailored to fit the needs of Chinese patients. For more information, visit us at: www.bostonscientific.cn.

奥博资本

Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages over USD$11 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 170 private companies across a wide range of therapeutic categories and stages of development, over 90 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well, with ~27×cumulative return in the past 20 years. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund, with approximately USD$200 million under management. OAP has made investments in 20 companies. 

铜牌赞助商

通和资本

Frontline BioVentures is a premier venture capital firm based in China, with offices in Shanghai, Suzhou, and Hong Kong. We specialize in investment of innovative life sciences companies with business focuses on strategic areas promoted by the Chinese government for growth and development.
 
Our investment professionals have proven track records both domestically and overseas and have valuable resources and extensive experiences in nurturing and scaling venture startups. We are intimately familiar with the landscape of pharma, biotech and medtech industry in the country.
 
We have a combined 85 years of experiences in the field of life sciences. Prior to Frontline BioVentures, our partners were venture capitalists, scientists, and serial entrepreneurs. Our team of seasoned professionals has a unique investment sense with a principled investment process that enables us to seize early signals for the next trend of the industries and stand ahead of curve.
 
In addition, we have accumulated a broad network of close ties with government agencies, CFDA, universities, research institutes, hi-tech parks, other institutional investors, domestic and multinational pharmaceutical and medtech companies, and leading venture capital firms in more established markets like the United States and Europe.
 
Our advisors are among the most respectable and senior specialists in life sciences who have built billion-dollar companies. Their domain expertise and networks provide Frontline BioVentures with competitive advantages in accessing capable and committed entrepreneurs and high quality deals, and maximizing the chance for our portfolio companies to succeed. 

 

元生创投

Sungent bioVENTURE was founded in Suzhou bioBAY on September 9th 2013 with a vision to be the best healthcare dedicated venture capital in China,

Our team manages approximately USD 90 Million of the 1st phase of fund, with distinguished scientific, medical, investment and extensive professional experience and tacking records in the healthcare industry.

The bioBAY, one of our leading investors own the best incubator and platform for life sciences start-ups in China, by levering the rich resources of bioBAY, we take more advantages and opportunities for investment continually.

Up to now, the excellent results on return of investment have been achieved from the previously invested startups, which are encouraging us to be the best venture capital firm for healthcare in China.

Dedicated for startups with growth potential, form biopharmaceuticals,medical devices, in-vitro diagnostics, to healthcare services, Sungent bioVENUTE is scouting the life sciences and healthcare industry for innovations that will bring people in better health and live longer.